Skip to main content
Premium Trial:

Request an Annual Quote

Japan Tobacco Is First Customer for Gene Logic's Database

Premium

COLUMBIA, Md.--Gene Logic here has announced that it will collaborate with Japan Tobacco to uncover drug targets and leads in kidney disease. Gene Logic will utilize its proprietary Accelerated Drug Discovery platform in the effort. Japan Tobacco will also be the first subscriber to Gene Logic's Gene Express Normal database of quantitative gene expression profiles in a variety of normal tissues of human, rat, and mouse origin. The deal also gives Japan Tobacco the option of accessing Gene Logic's Flow-thru Gene Chip technology for high-throughput screening.

Terms of the deal allow Japan Tobacco to expand the collaboration to other disease areas at any time during the first two years. The company will gain worldwide rights to all small-molecule drugs and therapeutic antibodies and proteins developed under the collaboration. Gene Logic will receive royalties on the sales of any such products, and retains the rights to gene therapy, antisense, and diagnostic products. The agreement also provides that Gene Logic will receive a minimum of $3 million a year from its partner over the predicted five-year life of the collaboration.

Filed under

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.